|
시장보고서
상품코드
2051256
바이러스성 결막염 치료제 시장 : 약제 클래스별, 바이러스 유형별, 유통 채널별, 지역별Viral Conjunctivitis Drugs Market, By Drug Class, By Virus Type, By Distribution Channel, By Geography |
||||||
바이러스성 결막염 치료제 시장은 2026년에 3억 9,490만 달러로 추정되며, 2033년까지 5억 6,680만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 5.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 3억 9,490만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 5.30% | 2033년 시장 규모 예측 : | 5억 6,680만 달러 |
바이러스성 결막염은 아데노바이러스, 헤르페스 바이러스 등 다양한 바이러스에 의해 발생하는 급성 결막염입니다. 바이러스성 결막염은 감염성 결막염의 대부분을 차지하며, 최대 75%를 차지합니다. 눈의 바이러스성 결막염의 특징으로는 충혈, 혈관 확장, 안구 분비물, 통증, 광시증 등이 있습니다. 아데노바이러스에 의한 바이러스성 결막염을 유행성 각결막염(EKC)이라고 합니다. 이 아데노바이러스과에는 인두결막염과 비특이적 여포성 결막염을 유발할 수 있는 다양한 혈청형이 포함되어 있습니다. 미국 안과학회(American Academy of Ophthalmology)의 2018년 논문에 따르면, 아데노바이러스성 결막염은 성인에서 가장 흔한 안구 감염 질환입니다. 아데노바이러스 결막염은 감염을 일으키는 바이러스가 주방 조리대나 유사한 표면에서 몇 주 동안 생존할 수 있기 때문에 감염력이 매우 강합니다.
시장 역학
시장 참여자들은 아데노바이러스성 결막염에 대한 보다 효과적인 치료법을 개발하기 위해 임상시험을 진행하고 있으며, 이는 예측 기간 동안 시장 성장에 기여할 수 있습니다. 예를 들어, 2017년 다케다제약의 자회사 Shire Plc는 아데노바이러스성 결막염을 앓고 있는 성인 및 소아 환자를 대상으로 SHP640의 안전성 및 유효성을 검증하기 위한 임상시험을 시작했습니다.
시장 관계자들은 신제품 출시에 집중하고 있으며, 이를 통해 세계 시장에서의 입지를 강화할 수 있을 것으로 기대하고 있습니다. 예를 들어, 2018년에는 애브비의 자회사인 아라간이 새로운 일반의약품(OTC) 인공눈물 제제인 '리프레쉬 리페어 윤활 점안제'를 출시했습니다. 본 제품은 카르복시메틸셀룰로오스(CMC), 히알루론산(HA, 불활성 성분), 삼투압 보호제가 함유되어 있어 안구건조증 등 결막염 증상으로 인한 유해한 영향으로부터 눈을 보호해줍니다.
시장 진출기업들은 유통 체계 강화를 위해 타사와의 제휴를 통해 세계 사업 확장을 추진하고 있으며, 이는 바이러스성 결막염 치료제 시장의 성장을 견인할 것으로 예측됩니다. 예를 들어, 2018년 제약회사 Mundipharma Deutschland GmbH &&Co. KG는 이탈리아 제약회사 NTC와 상업적 제휴를 맺고 라틴아메리카에서 안과용 의약품의 라이선스 및 판매에 대한 독점적 권리를 획득함으로써 안과 분야 제품 포트폴리오를 확대하였습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 바이러스성 결막염 치료제 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략, 향후 계획입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 바이러스성 결막염 치료제 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 참가자, 금융 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 바이러스성 결막염 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 바이러스성 결막염 치료제 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 바이러스성 결막염 치료제 시장 : 바이러스 유형별, 2021년-2033년
제6장 세계의 바이러스성 결막염 치료제 시장 : 유통 채널별, 2021년-2033년
제7장 세계의 바이러스성 결막염 치료제 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 섹션
LSH 26.06.18Viral Conjunctivitis Drugs Market is estimated to be valued at USD 394.9 Mn in 2026 and is expected to reach USD 566.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 394.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 566.8 Mn |
Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.
Market Dynamics
Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.
Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.
Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
- It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
- The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.
Market Segmentation
- Global Viral Conjunctivitis Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- Global Viral Conjunctivitis Drugs Market, By Virus Type (Revenue, USD Mn, 2021 - 2033)
- Adenovirus
- Enterovirus
- Others
- Global Viral Conjunctivitis Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Viral Conjunctivitis Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
- Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox
- NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Okogen Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Virus Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- Artificial tears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- Anti-histamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- NSAIDS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- Anti-Viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 -2033, (USD Mn)
- Segment Trends
5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Segment Trends
- Enterovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Segment Trends
- Others (Herpes Simplex Virus (HSV), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Segment Trends
6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Viral Conjunctivitis Drugs Market, By Region, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2021-2033, (USD Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2021-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bausch Health Companies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Panoptes Pharma Ges.m.b.H
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NovaBay Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Nicox, NanoViricides Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Santen Pharmaceutical Co.Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alcon
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Okogen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
